Baird has downgraded Resmed Inc (RMD) to Neutral from Outperform, effective December 15, 2025. The stock is currently priced at $253.07.
This move underscores increased caution regarding Resmed's outlook. Analysts suggest this revision may reflect concerns about competitive pressures and market conditions that could impact performance.
Resmed, headquartered in San Diego, California, specializes in digital health and cloud-connected medical devices. The company employs 10,600 full-time staff and focuses on developing solutions for respiratory disorders, including sleep disordered breathing and chronic obstructive pulmonary disease. With a market cap of $36.8 billion, Resmed has a P/E ratio of 25.60 and an EPS of 9.77.
Upcoming earnings are set for July 29, 2026, with an estimated EPS of $2.91 and revenue of $1.5 billion.
Analyst consensus indicates 5 Strong Buy, 12 Buy, 7 Hold, and 1 Strong Sell ratings, with a general consensus leaning towards Buy. Recent analyst actions include Baird's downgrade and several firms maintaining their ratings.
This update provides insight into the evolving analyst sentiment surrounding Resmed as it navigates a competitive landscape.